Liminal BioSciences Inc. (LMNL)
Upgrades & Downgrades
Latest LMNL news
Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder
13 July 2023
If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in A...
Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Managem...
12 July 2023
Liminal BioSciences Inc. LMNL, -1.33% stock is rallying 41.7% in premarket trades on Wednesday after the company said it agreed to go private at a price of $8.50 a share. Structured Alpha LP, a fund m...
Why Is Liminal Biosciences (LMNL) Stock Up 77% Today?
5 April 2023
Liminal Biosciences (NASDAQ: LMNL ) stock is taking off on Wednesday as investors react to the biopharmaceutical company getting an unsolicited transaction proposal. According to a press release from ...
Liminal Biosciences' stock soars 91% after getting takeover offer that's more than double its price
5 April 2023
Liminal Biosciences Inc.'s stock LMNL, -4.23% soared 91% in premarket trade Wednesday, after the company said it's received an unsolicited takeover offer of $7.50 a share from Structured Alpha LP. Tha...
Liminal BioSciences Inc. (LMNL) Q4 2022 Earnings Call Transcript
17 March 2023
Liminal BioSciences Inc. (NASDAQ:LMNL ) Q4 2022 Results Conference Call March 16, 2023 8:30 AM ET Company Participants Shrinal Inamdar - IR Bruce Pritchard - CEO Nicole Rusaw - CFO Conference Call Par...
Liminal BioSciences to Present at BIO CEO & Investor Conference
19 January 2023
LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Office...
Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript
13 November 2022
Liminal Biosciences (NASDAQ:LMNL ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations Bruce Pritchard - Chief Executive Officer Nic...
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript
13 May 2022
Liminal BioSciences Inc. (NASDAQ:LMNL ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Ch...
Liminal Biosciences to Present at Upcoming Investor Conferences
9 May 2022
LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced t...
Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022
20 January 2022
Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it would not be progressing the development of fezagepras fo...